Division of Sanofi
Latest From Ablynx NV
Novartis' Zolgensma and Pfizer's Vyndaqel were two of the early commercial standouts in 2019, on a likely blockbuster trajectory, while AbbVie's Skyrizi is poised to be fierce competitor in psoriasis.
AstraZeneca emerged as big pharma’s most active dealmaker over the 2014-2018 period, thanks to a combined surge in both in-licensing and out-licensing agreements.
Datamonitor report highlights big pharma’s licensing trends from last five years, and finds UK firm top on numbers of deals, but Merck & Co put up most money.
Public Company Edition: Bellus launched the first biopharma IPO in the US since mid-July and Vir Biotechnology, run by former Biogen CEO George Scangos, wants to raise $100m. Also, Turning Point's $202.5m offering and Zafgen's strategic review.
- Large Molecule
- Drug Delivery
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Immune Disorders
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Respiratory, Pulmonary
- Western Europe
- Parent & Subsidiaries
- Senior Management
Edwin Moses, PhD, CEO
Wim Ottevaere, CFO
Markus Ewert, PhD, CBO
Robert K Zeldin, MD, CMO
Heylen Johan, Chief Commerical Officer
Robert Friesen, PhD, CSO
- Contact Info
Phone: (32) 9 262 00 00
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.